Transthyretin mutagenesis: impact on amyloidogenesis and disease

Zaida L. Almeida,Daniela C. Vaz,Rui M. M. Brito

DOI: https://doi.org/10.1080/10408363.2024.2350379

IF: 7.721

2024-06-09

Critical Reviews in Clinical Laboratory Sciences

Abstract:Transthyretin (TTR), a homotetrameric protein found in plasma, cerebrospinal fluid, and the eye, plays a pivotal role in the onset of several amyloid diseases with high morbidity and mortality. Protein aggregation and fibril formation by wild-type TTR and its natural more amyloidogenic variants are hallmarks of ATTRwt and ATTRv amyloidosis, respectively. The formation of soluble amyloid aggregates and the accumulation of insoluble amyloid fibrils and deposits in multiple tissues can lead to organ dysfunction and cell death. The most frequent manifestations of ATTR are polyneuropathies and cardiomyopathies. However, clinical manifestations such as carpal tunnel syndrome, leptomeningeal, and ocular amyloidosis, among several others may also occur. This review provides an up-to-date listing of all single amino-acid mutations in TTR known to date. Of approximately 220 single-point mutations, 93% are considered pathogenic. Aspartic acid is the residue mutated with the highest frequency, whereas tryptophan is highly conserved. "Hot spot" mutation regions are mainly assigned to β-strands B, C, and D. This manuscript also reviews the protein aggregation models that have been proposed for TTR amyloid fibril formation and the transient conformational states that convert native TTR into aggregation-prone molecular species. Finally, it compiles the various in vitro TTR aggregation protocols currently in use for research and drug development purposes. In short, this article reviews and discusses TTR mutagenesis and amyloidogenesis, and their implications in disease onset.

medical laboratory technology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the impact of transthyretin (TTR) mutations on amyloidosis and diseases. Specifically, the paper focuses on the following aspects:

1. **Comprehensive list of TTR mutations**: The paper provides a detailed list of all currently known single - amino - acid mutations that have been found in TTR, and 93% of them are considered pathogenic. The mutations are mainly concentrated in the β - chain B, C, and D regions. In particular, aspartic acid is the most frequently mutated residue, while tryptophan is highly conserved.

2. **Molecular mechanisms of TTR amyloidosis**: The paper reviews the proposed protein aggregation models for TTR amyloid fibril formation and the transient conformational states that lead to the conversion of native TTR into aggregation - prone molecular species. These models help to understand how TTR changes from its normal tetrameric structure to amyloid fibrils.

3. **Experimental methods for TTR aggregation**: The paper also reviews various in vitro TTR aggregation protocols currently used for research and drug development. These methods are crucial for understanding the TTR aggregation process and developing treatment strategies.

4. **Clinical manifestations and pathological mechanisms**: The paper discusses different types of amyloidosis diseases caused by TTR mutations, such as wild - type TTR amyloidosis (ATTRwt) and hereditary TTR amyloidosis (ATTRv), including polyneuropathy (ATTRv - PN), cardiomyopathy (ATTRv - CM), meningeal amyloidosis (ATTRv - LM), and ocular amyloidosis (ATTRv - OC). The paper describes in detail the clinical manifestations, age of onset, survival period, and geographical distribution of these diseases.

Through the exploration of these aspects, the paper aims to provide researchers and clinicians with the latest review of TTR mutations and their roles in amyloidosis diseases, thereby promoting a deeper understanding of these diseases and the development of potential treatment methods.